CV
CapsoVision, Inc
$6.48
-1.37%
$328.3M
No data for this timeframe.
Vol
Market Cap$328.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders6 funds
Inst. Value$1.8M
Inst. Activity3 buys / 0 sells
Insider Activity1B / 0S
Insider Net $$83.40
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001378325·Prev Close $6.57
Recent Activity
May 14, 2026
earnings
CapsoVision Reports First Quarter 2026 Financial Results
<p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: C
May 5, 2026
Insider
Atkinson Douglas Patrick sold 34,786 shares
Head of Global Sales @ $0.5661 ($19.7K)
May 5, 2026
Insider
Atkinson Douglas Patrick sold 34,786 shares
Head of Global Sales @ $0.00 ($0.00)
May 4, 2026
Insider
Atkinson Douglas Patrick sold 36,036 shares
Head of Global Sales @ $0.2863 ($10.3K)
Apr 30, 2026
SEC
CapsoVision announced it will release Q1 2026 financial results on May 14, 2026, after market close, with a conference c
PRESS-RELEASE — Impact 2/10
Apr 23, 2026
SEC
CapsoVision's S-1 registration has become effective, allowing the company to proceed with its IPO. The offering, which i
EFFECT — Impact 5/10
Apr 17, 2026
SEC
CapsoVision is conducting a resale registration for 2.87 million shares issued in a private placement that raised $14 mi
S-1 — Impact 3/10
Inst.
VANGUARD GROUP INC — ADD
134,178 shares ($1.4M)
Price Targets
$10.00
+54.3% upside
Strong Buy
Current $6.48
Low $10.00
Median $10.00
High $10.00
1 analysts
$10.00
$10.00
Analyst Ratings
3Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 27, 2026 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
| Dec 31, 2025 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▼ -8.3% | $-0.13 — $-0.13 | -31% YoY | 1 |
| Next Q | $-0.12 ▼ -4.3% | $-0.12 — $-0.12 | 29% YoY | 1 |
| Current FY | $-0.52 ▼ -8.3% | $-0.52 — $-0.52 | 50% YoY | 1 |
| Next FY | $-0.42 ▼ -20.0% | $-0.42 — $-0.42 | 19% YoY | 1 |
Latest Reports
NEUTRAL
PRESS-RELEASE
2/10
CapsoVision announced it will release Q1 2026 financial results on May 14, 2026, after market close, with a conference c
Apr 30, 2026
NEUTRAL
EFFECT
5/10
CapsoVision's S-1 registration has become effective, allowing the company to proceed with its IPO. The offering, which i
Apr 23, 2026
MIXED
Press
6/10
CapsoVision reported Q4 and full-year 2025 earnings with revenue growth of 13% and 15% respectively, driven by increased
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.4M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $150.6K | NEW |
| MORGAN STANLEY | $101.2K | NEW |
| WELLS FARGO & COMPANY/MN | $67.2K | ADD |
| BANK OF AMERICA CORP | $37.8K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 5, 2026 | Atkinson Douglas | M | $19.7K |
| May 5, 2026 | Atkinson Douglas | M | $0.00 |
| May 4, 2026 | Atkinson Douglas | M | $10.3K |
| May 4, 2026 | Atkinson Douglas | M | $0.00 |
| Mar 19, 2026 | GOUW JULIA | A | $0.00 |
6 institutional holders with $1.8M total value (168,117 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 134,178 | $1.4M | 79.8% | ADD +92.9% |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 14,091 | $150.6K | 8.4% | NEW |
| 3 | MORGAN STANLEY | 9,463 | $101.2K | 5.6% | NEW |
| 4 | WELLS FARGO & COMPANY/MN | 6,287 | $67.2K | 3.7% | ADD +66.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 3,536 | $37.8K | 2.1% | ADD +40.9% |
| 6 | FMR LLC | 562 | $6.0K | 0.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 69,575 | 134,178 | +92.9% | $1.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 3,779 | 6,287 | +66.4% | $67.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 2,510 | 3,536 | +40.9% | $37.8K | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 69,575 | — | $336.7K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 14,091 | — | $68.2K | 2025-Q3 |
| MORGAN STANLEY | NEW | — | 9,600 | — | $46.5K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEW | — | 3,779 | — | $18.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 2,510 | — | $12.1K | 2025-Q3 |
7 unique insiders with 1 transactions. Net insider value: $83.40 ($83.40 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 5, 2026 | Atkinson Douglas Patrick | Head of Global Sales | M | 34,786 | $0.5661 | $19.7K |
| May 5, 2026 | Atkinson Douglas Patrick | Head of Global Sales | M | 34,786 | $0.00 | $0.00 |
| May 4, 2026 | Atkinson Douglas Patrick | Head of Global Sales | M | 36,036 | $0.2863 | $10.3K |
| May 4, 2026 | Atkinson Douglas Patrick | Head of Global Sales | M | 36,036 | $0.00 | $0.00 |
| Mar 19, 2026 | GOUW JULIA S | Director | A | 4,045 | $0.00 | $0.00 |
| Mar 19, 2026 | Kuo Hui Ying | Director | A | 4,045 | $0.00 | $0.00 |
| Mar 19, 2026 | Tsai Chen Lung | Director | A | 4,045 | $0.00 | $0.00 |
| Mar 19, 2026 | Imperial Joanne Carol | Director | A | 4,045 | $0.00 | $0.00 |
| Mar 19, 2026 | King Wen-Herng Henry | Director | A | 4,045 | $0.00 | $0.00 |
| Mar 19, 2026 | Harari Michele | Director | A | 4,045 | $0.00 | $0.00 |
| Jul 3, 2025 | Tsai Chen Lung | Director | BUY | 20 | $4.17 | $83.40 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.3/10.
NEUTRAL
PRESS-RELEASE
2/10
CapsoVision announced it will release Q1 2026 financial results on May 14, 2026, after market close,
Apr 30, 2026
NEUTRAL
EFFECT
5/10
CapsoVision's S-1 registration has become effective, allowing the company to proceed with its IPO. T
Apr 23, 2026
NEUTRAL
S-1
3/10
CapsoVision is conducting a resale registration for 2.87 million shares issued in a private placemen
Apr 17, 2026
MIXED
6/10
CapsoVision reported Q4 and full-year 2025 earnings with revenue growth of 13% and 15% respectively,
Mar 26, 2026
MIXED
6/10
CapsoVision announced preliminary, unaudited revenue of $3.9 million for Q4 2025 and $13.6 million f
Mar 20, 2026
NEUTRAL
3/10
CapsoVision announced it will release its Q4 and full-year 2025 financial results on March 26, 2026,
Mar 12, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 3 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$10.00 mean target
+54.3% upside
Strong Buy (1.00)
$10.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $6.48 |
| Target Low | $10.00 |
| Target Mean | $10.00 |
| Target Median | $10.00 |
| Target High | $10.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.13 | $-0.13 | -31.4% | -8.3% | 0↑ 1↓ | $0.0B | 15.0% | 1 |
| Next Q 2026-09-30 |
$-0.12 | $-0.12 | $-0.12 | 29.4% | -4.3% | 1↑ 0↓ | $0.0B | 16.4% | 1 |
| Current FY 2026-12-31 |
$-0.52 | $-0.52 | $-0.52 | 49.5% | -8.3% | 1↑ 1↓ | $0.0B | 14.9% | 1 |
| Next FY 2027-12-31 |
$-0.42 | $-0.42 | $-0.42 | 19.2% | -20.0% | 0↑ 1↓ | $0.0B | 37.9% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.130 | |
| 7d ago | $-0.120 | -0.010 |
| 30d ago | $-0.120 | -0.010 |
| 60d ago | $-0.115 | -0.015 |
| 90d ago | $-0.115 | -0.015 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 27, 2026 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
| Dec 31, 2025 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
CapsoVision Reports First Quarter 2026 Financial Results
<p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company
May 14, 2026
earnings_calendar
CV Q1 2026 Earnings Scheduled — 2026-05-14
Apr 30, 2026
earnings
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
<p>SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing adv
Apr 30, 2026
short_interest
FTD: CV — 217,513 shares ($1.4M) failed to deliver
Settlement: 20260430, Price: $6.40, FTD Value: $1,392,083.2, CAPSOVISION INC COM
Apr 9, 2026
short_interest
FTD: CV — 180,100 shares ($1.1M) failed to deliver
Settlement: 20260409, Price: $6.14, FTD Value: $1,105,814, CAPSOVISION INC COM
Apr 8, 2026
short_interest
FTD: CV — 178,746 shares ($1.1M) failed to deliver
Settlement: 20260408, Price: $6.27, FTD Value: $1,120,737.42, CAPSOVISION INC COM
Apr 6, 2026
Enforcement
HSR Early Termination: Tillman Towers US CV, LP; Tillman Global Holdings V LLC
The FTC granted early termination of the HSR Act waiting period for a transaction involving Tillman Towers US CV, LP; Tillman Global Holdings V LLC.
Mar 27, 2026
short_interest
FTD: CV — 176,085 shares ($1.3M) failed to deliver
Settlement: 20260327, Price: $7.53, FTD Value: $1,325,920.05, CAPSOVISION INC COM
Mar 26, 2026
earnings
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
<p>SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing adv
Mar 26, 2026
earnings_calendar
CV Q4 2025 Earnings Scheduled — 2026-03-26
Mar 26, 2026
short_interest
FTD: CV — 231,926 shares ($1.9M) failed to deliver
Settlement: 20260326, Price: $8.27, FTD Value: $1,918,028.02, CAPSOVISION INC COM
Mar 23, 2026
short_volume
Short Volume: CV — 61.9% short (0.4M / 0.7M)
Short: 424,678 | Exempt: 1,031 | TRF Vol: 686,603 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_interest
FTD: CV — 86,925 shares ($0.6M) failed to deliver
Settlement: 20260323, Price: $6.87, FTD Value: $597,174.75, CAPSOVISION INC COM
Mar 20, 2026
earnings
CapsoVision Announces $14 Million Private Placement Financing
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results <pre>Reports Preliminary, Unaudited Fourth-Quarter and Full Year 20
Mar 12, 2026
earnings
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
Mar 9, 2026
other
CapsoVision to Participate in the 38th Annual ROTH Conference
CapsoVision to Participate in the 38th Annual ROTH Conference